bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

1

Inhibiting Mycobacterium tuberculosis ClpP1P2 by

2

addressing the equatorial handle domain of ClpP1 subunit

3
4

Yang Yang1#, Yibo Zhu1#, Tao Yang1#, Tao Li1, Yuan Ju1, Yingjie

5

Song1, Jun He1, Huanxiang Liu2, Rui Bao1* and Youfu Luo1*

6

1

7

West China Hospital, Sichuan University, Chengdu, 610041, China

8

2

Center of Infectious Diseases, State Key Laboratory of Biotherapy,

School of Pharmacy, Lanzhou University, Lanzhou, 730000, China

9
10
11
12
13

*Address correspondence to R.B. and Y.F.L.

14

E-mail: baorui@scu.edu.cn; luo_youfu@scu.edu.cn

15
16
17
18

# These authors contributed equally to this work.

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

19

Abstract

20

Unlike other bacterial ClpP systems, mycobacterial ClpP1P2 complex is essential

21

for mycobacterial survival. The functional details of Mycobacterium tuberculosis (Mtb)

22

ClpP1P2 remains largely elusive and selectively targeting ClpP of different species is a

23

big challenge. In this work, cediranib was demonstrated to significantly decrease the

24

activity of MtbClpP1P2. By solving the crystal structure of cediranib-bound

25

MtbClpP1P2, we found that cediranib dysregulates MtbClpP1P2 by interfering with

26

handle domain of the equatorial region of MtbClpP1, indicating that the inter-ring

27

dynamics are crucial for its function. This finding provides direct evidence for the

28

notion that a conformational switch in the equatorial handle domain is essential for ClpP

29

activity. We also present biochemical data to interpret the distinct interaction pattern

30

and inhibitory properties of cediranib toward MtbClpP1P2. These results suggest that

31

the variable handle domain region is responsible for the species-selectivity of cediranib,

32

which suggests the equatorial handle domain as a potential region for screening

33

pathogen-specific ClpP inhibitors.

34

Introduction

35

Caseinolytic protease ClpP, a widely conserved self-compartmentalizing serine

36

protease in bacteria, plays essential roles in protein metabolism and regulates diverse

37

physiological functions including cell motility, genetic competence, cell differentiation,

38

sporulation, and virulence, and is thus an attractive target for antibiotic development[1-

39

8]. Notably, ClpP is an novel drug target for which both inhibition and activation result

40

in an attenuated or lethal phenotype in many pathogens; thus agonists and antagonists
2 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

41

aimed at the ClpP system represent promising drug candidates for further evaluation[9,

42

10]. The ClpP enzyme of Mycobacterium tuberculosis (MTB), MtbClpP1P2, exerts its

43

proteolytic function by a heterotetramer of two protein subunits, ClpP1 and ClpP2[11,

44

12]. Moreover, encoding genes of subunits ClpP1 and ClpP2, have been shown to be

45

essential genes for MTB survival and the deletion of either gene causes bacterial

46

death[13]. A panel of MtbClpP1P2 inhibitors have been reported and they can be

47

classified into two categories depending on their action modes. The first kind of small

48

molecules act on the catalytically active center, covalently modifying the serine

49

residues of the active sites of two subunits of MtbClpP1P2, including bortezomib,

50

boron-containing analogues and beta lactones[14-17]. The second kind of inhibitors act

51

on the chaperone protein (ClpX/ClpC1) binding site that competitively binds to the

52

surface of the ClpP2 subunit. Representative molecules of this category are ADEP and

53

its analogs[12]. Since the chaperones binding L/IGF region of ClpP2 subunit is highly

54

conserved, as with the inhibitor of the MtbClpP1P2 catalytic center[18], the ADEP

55

compounds are nonselective as well. As we know, the off-target effects may bring

56

severe side effects during drug development. Thus it is desirable to find novel binding

57

pocket or selective inhibitors targeting MtbClpP1P2 to avoid the potential adverse

58

effects of nonselective ones. In this work, we demonstrate that cediranib, an orally

59

available vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, is able to

60

inhibit MtbClpP1P2 peptidase activity. We solved the crystal structure of MtbClpP1P2

61

in complex with an agonist peptide and cediranib, and present details of the inhibitory

62

mechanism. Unlike other ClpP inhibitors, cediranib dysregulates MtbClpP1P2 by
3 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

63

interfering with the equatorial region of MtbClpP1, supporting the idea that the inter-

64

ring dynamics are crucial for ClpP function. We also present biochemical data

65

suggesting that this mechanism is distinct from those of previously reported ClpP

66

inhibitors. These results reveal a novel druggable pocket in MtbClpP1P2, with potential

67

implications for further research on ClpP catalytic mechanism and drug development.

68

Results

69

Identification of cediranib as a novel inhibitor of MtbClpP1P2

70

We screened about 2600 bioactive compounds (MedChemExpress, HY-L001)

71

based on a peptidase activity assay. Eight compounds (hit rate 0.31%) that generated

72

‚â•80% inhibition of MtbClpP1P2 were selected for IC50 value evaluation (Fig 1A).

73

Among these hits, cediranib and brivanib, which possesses an indolyl group, showed

74

promising inhibitory effects toward MtbClpP1P2 peptidase activity; cediranib had a

75

lower IC50 value (3.4 ŒºM) than brivanib (12.5 ŒºM) (Fig 1A and 1B). In addition,

76

cediranib (100ŒºM) led to a peak shift of 10¬∞C in the thermal stability of MtbClpP1P2

77

in differential scanning calorimetry (DSC) assay, which confirms their direct interaction

78

in solution (S1 Fig).

79

To dissect whether cediranib is a species-selective inhibitor, we profiled its

80

peptidase inhibitory effects against a panel of ClpPs from Escherichia coli (EcClpP),

81

Pseudomonas aeruginosa (PaClpP1), and Staphylococcus aureus (SaClpP) (Table 1

82

and S2 Fig). The results show that cediranib has no obvious inhibitory effect on those

83

ClpP variants. In contrast, cediranib demonstrated non-competitive inhibition of

84

MtbClpP1P2 (Fig1C), indicating that it may not form covalent bonds with the protease.
4 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

85

To validate the antibacterial activity of cediranib, we carried out growth inhibition

86

assays on several pathogenic bacteria. As Table 1 and Table 2 show, cediranib had no

87

inhibitory activity toward S. aureus, P. aeruginosa, Escherichia coli and Enterococcus

88

faecalis (minimum inhibitory concentration [MIC] >128 Œºg/mL), while it was toxic to

89

E. faecium, Staphylococcus epidermidis, Klebsiella pneumoniae and Mycobacterium

90

smegmatis MC2155 (MIC 64 Œºg/mL). Cediranib inhibited the growth of Mtb H37Rv

91

with an MIC value of 16 Œºg/mL. Therefore, cediranib exhibits species-selectivity in

92

suppressing pathogen growth. Next, we performed peptidase assay on human ClpP

93

(hClpP) to estimate the toxicity of cediranib to human mitochondria. As shown in Table

94

1 and S2 Fig, cediranib displayed weak inhibition of hClpP activity compared to

95

MtbClpP1P2, with a selectivity index >10.

96

To gain insights into the inhibitory mechanism of cediranib, we purified and

97

crystallized MtbClpP1P2 in complex with cediranib and benzoyl-Leu-Leu (Bz-LL).

98

The crystals belonged to space group C121 and diffracted to 2.7 √Ö resolution. The

99

structure was determined by molecular replacement using the previously solved

100

MtbClpP1P2 structure (PDB code 5DZK) as a search model, and the final model was

101

refined to an Rfactor of 20.02% (Rfree =24.33%) (Table 3)[19]. The asymmetric unit

102

has one hetero-tetradecameric complex structure composed of heptameric ClpP1 and

103

ClpP2 rings (Fig 2A). The organization and overall structure remain identical to those

104

in

105

structures[12, 19], presenting an open-pore conformation with 30 and 25 √Ö diameters

106

in the ClpP1 and P2 rings, respectively (Fig 2B).

benzyloxycarbonyl-Ile-Leu

(Z-IL)-bound

5 / 42

and

Bz-LL-bound

MtbClpP1P2

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

107

MtbClpP1 and MtbClpP2 share high sequence identity (48%) and have a common

108

core structure, which adopts an Œ±/Œ≤-fold consisting of two central twisted Œ≤-sheets

109

flanked by seven Œ±-helices and an extended handle domain (Fig 2C). The N-terminal

110

regions of MtbClpP2 are in an extended Œ≤-hairpin conformation, and are further

111

stabilized by the MtbClpP2 ring from the crystallographic symmetry unit. The typical

112

catalytic triad (Ser-His-Asp) locates in the cleft between the core domain and the handle

113

domain; all 14 active sites distribute on the inner surface of the assembled MtbClpP1P2

114

complex and eventually form the hydrolytic chamber. Bz-LL peptides occupied all

115

cleavage centers in the MtbClpP1ClpP2 tetradecamer, whereas seven cediranib

116

molecules bound within the cleft between MtbClpP1 monomers.

117

Self-association is a common and well-conserved property of Clp protease. The

118

inter-ring interactions are mediated by the handle domain, a strand-turn-helix motif that

119

forms the equatorial regions of the ClpP barrel[20-24]. Compared with the Bz-LL-

120

bound MtbClp1Clp2 structure[19], the additional binding of cediranib slightly reduced

121

the interface area between MtbClpP1 monomers (from 1356 √Ö2 to 1116 √Ö2), but does

122

not change the assembly state of the whole complex, suggesting that the inhibitory

123

mechanism of cediranib is different from that of compounds that disrupt the

124

oligomerization of the ClpP complex[25].

125

Cediranib-bound MtbClpP1P2 structure reveals a novel inhibitor binding-site

126

As previously reported[12, 19], the binding sites of Bz-LL and Z-IL are aligned

127

parallel to Œ≤-strands 6 and 8 in each subunit and the agonist peptides form several

128

hydrogen bonds with protein main-chain atoms. However, because MtbClpP2 has a
6 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

129

longer loop after the Œ≤G strand (residues 127‚Äì129) and thus generates a shallower S1

130

pocket, Bz-LL is bound in opposite orientations in MtbClpP1 and MtbClpP2 (Fig 3A),

131

supporting the notion that MtbClpP1 and MtbClpP2 have different substrate

132

specificities[26]. In MtbClpP1, around the Bz-LL binding site, the averaged 2Fo‚àíFc

133

electron-density map allowed us to unambiguously build the cediranib molecules

134

between Œ±5 and Œ±3 (Fig 3B and 3C). Cediranib binds this site predominantly via

135

hydrophobic interactions, while its indolyl group forms a cation‚ÄìœÄ interaction with

136

Arg119 (Fig 2D). Additionally, the quinazoline ring of cediranib interacts with the

137

aromatic rings from Trp174 and the benzoyl group of Bz-LL, resembling a œÄ‚ÄìœÄ stacking

138

interaction. In contrast to MtbClpP1, the corresponding sites in MtbClpP2 generate a

139

more compact pore, where Œ±5 moves closer to Œ±3 and the large side chains of Met160

140

and Phe83 restrict accessibility to this pocket, making cediranib unable to bind to

141

MtbClpP2 (Fig 3D).

142

Unlike the peptidyl inhibitors that occupy the S1‚ÄìS3 subsites of ClpP[27],

143

cediranib does not directly interact with the active site, but interferes with the dynamic

144

handle region, which was proposed to be responsible for product release[21, 28](Fig

145

3C and 3E). Though a small channel in the variable handle region of MtbClpP1 was

146

observed in ADEP-MtbClpP1P2 complex in previous study[12], we firstly

147

demonstrated this small channel could be occupied by a small molecule, herein

148

cediranib, and be employed to realize MtbClpP selectivity. As Fig 3F illustrates, the

149

cediranib-binding pocket is formed by Œ±5 (residues Gln142‚ÄìGlu149), Œ±3 (residues

150

Ile71‚ÄìAla76) and three short Œ≤-sheets (Œ≤D, Œ≤F, Œ≤H) from the neighboring ClpP1 subunit.
7 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

151

It is worth noting that Œ±5 is the major part of the handle domain.

152

Molecular dynamics simulation studies revealed cediranib interferes the

153

conformational changes of MtbClpP1

154

Previous molecular dynamics simulation studies on SaClpP revealed that Œ±5

155

adopts a kinked conformation by breaking the helix at residue Lys145 (corresponding

156

to Val145 in MtbClpP1)[24]. During the reaction cycle, the handle domain undergoes

157

an unfolding/refolding process, allowing the whole cylindrical ClpP barrel to adopt

158

extended, compact and compressed states[23, 24, 29-31]. In order to analysis the effect

159

of cediranib on the dynamic transition of handle domain, we performed a 500-ns MD

160

simulation on MtbClpP1 dimer (chain B and M) with/without cediranib (S3 Fig). The

161

r.m.s. deviation (RMSD) values of CŒ± from the head domain and handle domain were

162

monitored, the results indicated that handle domain underwent dramatic conformational

163

changes during the simulation, whereas both the head domain and handle domian of B

164

chain was more stable than that of M chain( S3A Fig and S3C Fig). Next, the secondary

165

structure transformation of handle domain were calculated along the trajectory of

166

simulation by DSSP[24] (S3B Fig and S3D Fig). The profile revealed that the N-

167

terminal part of helix E (residues 133‚Äì158) underwent a helical unfolding/refolding

168

process. In the absence of cediranib, the N-terminal part (residues 133‚Äì137) in chain B

169

primarily adopted turn structure in 0-350 ns. Then, residues 133‚Äì154 adopted coil , turn

170

and 3-10Helix structures. In chain M, residues 143‚Äì147 mainly adopted turn structure.

171

With binding of cediranib, the N-terminal part(residues 133‚Äì137) of chain B adoped

172

coil and turn strcture in the initial stage (0‚Äì300 ns). Subsequently(300-500ns), these
8 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

173

residues gradually readopted some 3-10Helix and Œ±-helix. By contrast to chain B, chain

174

M was much more unstable, particularly at 250ns, most Œ±-helix structure adopted turn

175

and coil (S3B Fig and S3D Fig). To identify the most significant motions of handle

176

domain of MtbClpP1 dimer induced by cediranib, we performed PCA using the MD

177

trajectory[24]. As shown in S3E Fig and S3F Fig, during the conformational transition,

178

four intermediate conformations (see the 50-ns, 100-ns,300-ns, and 500-ns snapshots

179

in Fig 3E and 3F) was observed. Based on the results of MD simulation and PCA, we

180

constructed a rough energy landscape for the conformational transition of MtbClpP1

181

dimer projected onto the first two principal components, PC1 and PC2. Obviously, the

182

binding of cediranib to MtbClpP1 interferes the conformational changes, likely

183

preventing the protease from accomplishing the enzymatic process.

184

Mutagenesis and functional analysis of the cediranib-binding site

185

As we known, the ClpPs from different species share high sequence similarity

186

(55.0‚Äì90.9%) and conserved overall structure (Fig 4A). Consistently, the general and

187

critical gating mechanism of ClpP requires the handle domain to preserve its structural

188

integrity[29]. In the dynamic region of the handle domain (Ser132‚ÄìVal145 in

189

MtbClpP1), several sites involved in structural stabilization have been identified to be

190

important for ClpP function: Gln132/Glu135 in SaClpP (corresponding to

191

Ser132/Asp135 in MtbClpP1, interacting with Arg171)[23]; Ile149/Ile151 in EcClpP

192

(corresponding to Ile136/Ile138 in MtbClpP1)[21]; and Ala153 in Streptococcus

193

pneumoniae ClpP (corresponding to Ala140 in MtbClpP1) (Fig 3F)[22]. Thus, the

194

cediranib-bound MtbClpP1P2 structure provides additional evidence to highlight the
9 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

195

critical role of the handle region.

196

To investigate the residues in the cediranib-binding pocket, we introduced

197

different mutations in relevant sites based on sequence alignment (Fig 4B and Table 4).

198

Consistent with the importance of the equatorial pore and handle domain, most site-

199

directed mutations in the selected sites decreased or abolished MtbClpP1P2 activity.

200

Considering Ile71, Met75, Ile146 and Trp174, even when residues with similar side

201

chains were substituted in those sites, the enzyme activity was not retained, suggesting

202

there are constraints on both residue size and chemical properties to maintain the local

203

structural integrity and flexibility (Table 4 and Fig 4C).

204

An electrostatic interaction between two MtbClpP1 subunits (Arg119‚ÄìGln142)

205

(Fig 3F) seems to be an important factor mediating the side pore gating, because any

206

substitution that changed the charge properties of either site resulted in reduced or

207

abolished activity. In contrast, sites Met95 and Glu149 of MtbClpP1 exhibit various

208

levels of tolerance to mutation. In particular, Met95Gln and Glu149Leu variants retain

209

activity and have altered sensitivity of MtbClpP1P2 to cediranib, providing a structural

210

basis for the specific recognition between cediranib and MtbClpP1 (Table 4).

211

Discussion

212

ClpP represents a unique type of serine protease complex responsible for the

213

proteolysis of damaged or misfolded proteins. Because it plays critical roles in the

214

regulation of infectivity and virulence of many bacterial pathogens and is involved in

215

various human diseases, interfering with ClpP activity has been evaluated as a potential

10 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

216

therapeutic strategy in the treatment of different ailments[32]. In-depth understanding

217

of the mechanism of ClpP reaction and regulation is crucial for development of

218

chemotherapeutic agents that target this protein. The importance of the dynamic

219

equatorial region in ClpP has long been recognized[21-24, 29-31].

220

As the first identified inhibitor targeting flexible handle region of ClpP, cediranib

221

shows a distinct inhibitory mechanism. The cediranib-bound MtbClpP1P2 complex

222

structure provides valuable evidence to support the important roles of equatorial handle

223

domain for ClpP function[21][26]. Compared with the highly conserved critical residues

224

in the N-terminal region of Œ±5 (Ile136, Ile138, and Ala140 in MtbClpP1) (Fig 4C),

225

residues participating in cediranib binding are relatively diverse among different ClpP

226

homologs, leading to a substantial variation in the size of the binding pockets near to

227

the side pores, which suggests this mechanism could be employed for pathogen-

228

selective ClpP inhibitor development.

229

Materials and Methods

230

Bacterial strains and culture conditions. Escherichia coli DH5Œ± and BL21 (DE3)

231

were cultured at 37¬∞C in Luria broth (LB) and LB-agar plates. DNA encoding M.

232

tuberculosis ClpP1 and ClpP2 (spanning residues 7‚Äì200 and 13‚Äì214, respectively) was

233

cloned into a pRSF-Duet vector preceded by an N-terminal His6-SUMO tag

234

(Novagen)[11, 12]. Full-length EcClpP, SaClpP, PaClpP1 and the hClpP gene without

235

its mitochondrial targeting sequence (residues Met1‚ÄìPro57) were also respectively

236

cloned into pRSF-Duet preceded by an N-terminal His6-SUMO tag[33-35]. PCR was

237

performed with PrimeSTAR¬Æ max DNA polymerase (Takara) and Ex Taq¬Æ polymerase
11 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

238

(Takara). The plasmids carrying distinct ClpP genes were transformed into Escherichia

239

coli BL21 (DE3) cells (TransGen Biotech). The plasmids and primers used in this study

240

are listed in Appendix Table S1 and Appendix Table S2.

241

Protein expression and purification. M. tuberculosis ClpP1 (residues 7‚Äì200) and

242

ClpP2 (residues 13‚Äì214) with N-terminal His6-SUMO tags were expressed and purified

243

as described, with minor modifications[11, 12, 14]. In short, ClpP1 and ClpP2 were

244

individually overexpressed in E. coli strain BL21 (DE3) in LB broth at 16¬∞C, following

245

induction with 0.5 mM isopropyl Œ≤-D-1-thiogalactopyranoside for about 16 h with

246

shaking at 220 rpm in medium supplemented with 50 Œºg/mL kanamycin. Cells were

247

resuspended and lysed in buffer containing 50 mM K2HPO4/KH2PO4, pH 7.6, 500 mM

248

KCl, 10% glycerol and 0.5 mM dithiothreitol. His-tagged MtbClpP1/MtbClpP2

249

proteins were purified using a nickel affinity column and eluted with the same buffer

250

supplemented with 250 mM imidazole. The His6-SUMO tag of eluted proteins was

251

removed using ubiquitin-like-protease 1 (ULP1) at 4¬∞C. The tag-free proteins were

252

further purified by anion exchange chromatography (MonoQ; GE Healthcare). Peak

253

fractions were collected, concentrated and applied to Superdex 200 16/600 (GE

254

Healthcare) preequilibrated with buffer containing 10 mM HEPES, pH 7.5, 50 mM

255

NaCl and 2 mM dithiothreitol for final purification. Purified ClpP1 and ClpP2 were

256

concentrated in Amicon centrifugal concentration devices (Millipore) to >80 ŒºM

257

tetradecamer. EcClpP, SaClpP, PaClpP1 and hClpP proteins were expressed as

258

described above. These proteins were purified using a nickel affinity column and then

259

incubated with ULP1 at 4¬∞C to cleave the His6-SUMO tag[36].
12 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

260

Compound screening. The peptidase activity of MtbClpP1P2 was monitored at 30¬∞C

261

in black 96-well plates, as described[11, 14]. After peptide bond cleavage, the

262

fluorophore 7-amino-4-methylcoumarin of the fluorogenic substrate Z-Gly-Gly-Leu-

263

AMC is liberated and can be quantified. Briefly, each well contained 100 ŒºM

264

fluorogenic peptide, 0.5 ŒºM tetradecamer ClpP1P2, and 2 mM Bz-LL in 80 ŒºL of buffer

265

containing 50 mM phosphate buffer, pH 7.6, 300 mM KCl, 5 mM MgCl2 and 5%

266

glycerol. Substrate cleavage was monitored using an all-in-one microplate reader (Gen5;

267

BioTek) by exciting at 380 nm and following the increase in fluorescence emission at

268

460 nm. The deviation of fluorescence value in at least two independent measurements

269

was ‚â§5%. The screening assay was carried out in 96-well format as described above,

270

and about 2600 compounds were screened at 100 ¬µM. Positive (bortezomib) and

271

negative controls (dimethyl sulfoxide; DMSO) were included on every plate and were

272

used to assess the performance of the primary screen. Bz-LL was purchased from GL

273

Biochem (Shanghai) Ltd. Cediranib was purchased from MedChemExpress.

274

IC50 determination. To determine the potency of the 8 ‚Äúhit‚Äù compounds against

275

MtbClpP1P2, these compounds were tested at concentrations ranging from 1 to 100 ÔÅ≠M

276

in a 96-well plate format. The reaction mix contained 0.5 ÔÅ≠M MtbClpP1P2

277

tetradecamer and 2 mM Bz-LL, with 0.8 ÔÅ≠L of each dilution of the compound or DMSO

278

in a total volume of 80ÔÄ†ÔÅ≠L. The reaction was initiated by addition of 0.8 ÔÅ≠L of 10 mM

279

fluorogenic substrate Z-Gly-Gly-Leu-AMC (100 ÔÅ≠M final concentration) to the

280

reaction mix. Initial velocity data was obtained by the monitoring increase in the

281

fluorescence due to hydrolysis of the substrate using the microplate reader at 10-min
13 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

282

intervals over 60 min. The IC50 value for each compound was obtained by nonlinear

283

regression curve fitting of a four-parameter variable slope equation to the dose‚Äì

284

response data using Prism software.

285

The peptidase activity of EcClpP, SaClpP, PaClpP1 and hClpP was determined using a

286

fluorescence-based assay with Suc-LY-AMC as the substrate, according to literature

287

protocols[33-35]. The reaction mix contained 0.5 ÔÅ≠M EcClpP/2.5 ÔÅ≠M SaClpP/0.5 ÔÅ≠M

288

PaClpP/3 ÔÅ≠M hClpP tetradecamer, with 0.8 ÔÅ≠L of each dilution of the test compound

289

or DMSO in a total volume of 80ÔÄ†ÔÅ≠L. The IC50 values for cediranib against EcClpP,

290

SaClpP, PaClpP1 and hClpP were obtained as described above.

291

Non-competitive inhibition was investigated by using 0.5 ÔÅ≠M MtbClpP1P2

292

tetradecamer and 2 mM Bz-LL with different concentrations of cediranib. An

293

equivalent volume of DMSO was added to the control group. The serially diluted

294

substrate (500, 400, 300, 200, 100 and 50 ŒºM) was added into wells of a 96-well plate

295

and incubated for 30min at room temperature. Fluorescence was measured at 30¬∞C

296

using the microplate reader (excitation, 380 nm; emission, 460 nm) for 1 h[9].

297

Crystallization. Cediranib-MtbClpP1P2 complex crystals were prepared by the

298

hanging drop method referring to previously published works[12, 19]. The precipitant

299

solution consisted of 1.5 M (NH4)2SO4 and 0.1 M MES, pH 6.5. A drop contained a

300

mixture of 2 ŒºL protein (about 2.5 mg/mL ClpP1 and ClpP2, 0.2 mM cediranib maleate,

301

5 mM Bz-LL, 10 mM HEPES, 50 mM NaCl, 2 mM DTT, pH 7.5) and 2 ŒºL of

302

precipitant solution and was incubated at 18¬∞C for about 3 months. Crystals were

303

soaked briefly in 2 M Li2SO4 solution and were stored in liquid nitrogen.
14 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

304

Data collection and structure determination. The X-ray data were collected with a

305

CCD camera at station BL-19U of the Shanghai synchrotron radiation facility (SSRF),

306

Shanghai, China. The diffraction data were indexed, integrated, and scaled using the

307

HKL2000 program suite[37]. The process of structure building and refinement was

308

monitored using the COOT and PHENIX suites[38, 39]. The PDB code for the co-

309

crystal structure of cediranib with MtbClpP1P2 (resolution 2.7 √Ö) is 6IW7.

310

DSC. DSC-based analysis of the thermal denaturation of proteins provides an approach

311

for measuring protein‚Äìligand interactions[40]. Samples for DSC were prepared

312

following the operating manual of the instrument. MtbClpP1P2 was dissolved to a final

313

concentration of 0.5 mg/mL. The molar ratio between MtbClpP1P2 and compounds

314

was 10:1 in reaction cells. DSC measurements were performed using a VP-DSC Micro

315

Calorimeter (Microcal, USA) at a scan rate of 0.5‚Äì2¬∞C/min in the temperature range

316

10‚Äì110¬∞C. Six-pair blank cells with buffer (50 mM phosphate buffer, pH 7.6, 300 mM

317

KCl, 5 mM MgCl2 and 5% glycerol, with the same volume of DMSO) were prepared

318

to obtain instrumental baselines, which were systematically subtracted from the sample

319

experimental thermograms. A thermal transition curve was obtained from a plot of heat

320

capacity against temperature.

321

Mutagenesis. Thirty-one mutations were introduced by site-directed mutagenesis,

322

primers are listed in Appendix Table S3. The PCR products were extracted with PCR

323

purification kits (Takara 9761) and ligated using a Blunting Kination Ligation Kit

324

(Takara 6217). The mutated sequences of the ClpP1 gene were confirmed by DNA

325

sequencing (Tsingke). Variant ClpP1 proteins were expressed in Escherichia coli BL21
15 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

326

(DE3) for enzymatic cleavage assays. The IC50 values of cediranib toward MtbClpP1P2

327

mutants were determined in the same way as that for wild-type MtbClpP1P2.

328

Molecular Dynamics Simulations. The molecular dynamics simulations were

329

performed in AMBER 14 software package[41]. The initial coordinates for molecular

330

dynamics simulation were firstly prepared through structural inspection and

331

optimization in Schr√∂dinger software suite[42]. In the tleap module of AMBER,

332

MtbClpP1P2 dimer was solvated in a rectangular water box of TIP3P and neutralized

333

with Na+ ions. The periodic boundary conditions were setup with all the solvents 10 √Ö

334

away from the solutes. The protein were parameterized using the AMBER FF99SB

335

force field[43] and the ligands were parameterized using the GAFF force filed[44].

336

Energy minimization was performed firstly to remove the local atomic collision in the

337

systems and the combination of the descent steepest with conjugated gradient method

338

was adopted in the process. In the NVT ensemble, the systems were heated from 0 to

339

310 K gradually and the solutes were restrained with harmonic force constant 5

340

kcal/mol/√Ö2 simultaneously. Five equilibration stages were performed to adjust the

341

solvents density. Finally, 500ns conventional molecular dynamics (cMD) simulations

342

were performed in the NPT ensemble, with coordinates saved every 5 ps throughout the

343

entire process.

344

Data analysis for MD simulation. Root-mean-square deviation (RMSD) for the

345

proteins and ligands during the simulations were calculated using the CPPTRAJ

346

module[45] of AmberTools 13 package[41] to characterize the conformational change

347

of the proteins and ligands. Standardized secondary structures assignment analysis were
16 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

348

calculated with the DSSP algorithm using the AmberTools 13 package, which can

349

characterize the propensities of secondary structures for each residue during the

350

simulations. Then the heatmap for DSSP analysis was plotted using the MATLAB

351

package (MathWorks, USA).Principal Component Analysis (PCA) analysis on the

352

basis of covariance matrix was carried out using the program Carma[46] to address the

353

collective motions of MtbClpP1P2. A two-dimensional representation of Free Energy

354

Landscape (FEL) was built based on the PCA analysis, and two dominant components

355

of PC1 and PC2 were selected as the reaction coordinates. The FEL along the reaction

356

coordinates could be calculated using the following equation[47]:

357

‚àÜG(PC1, PC2) = ‚àíŒ∫ùêµ ùëáln g(PC1, PC2)

358

where T and ƒ∏B represent the temperature of MD simulations and the Boltzmann

359

constant, respectively. The g(PC1,PC2) is the normalized joint probability. Then the

360

structures for the lowest energy in FEL were extracted as the representative

361

conformation of each energy basin. These representative structures were superimposed

362

to the initial crystal structure for comparison.

363

Acknowledgements

364

We would like to thank Professor Jikui Song for generously sharing the plasmids used

365

to generate ClpPs proteins. X-ray diffraction image collection, analysis and

366

computation work were performed using the workstations at Shanghai Synchrotron

367

Radiation Facility.

368

Author contributions

369

Conceptualization: Youfu Luo.
17 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

370

Data curation:Yang Yang, Yibo Zhu and Huanxiang Liu.

371

Formal analysis: Yang Yang, Yibo Zhu,Tao Yang, Tao Li, Yuan Ju, Yingjie Song,

372

Huanxiang Liu, Jun He, Rui Bao and Youfu Luo.

373

Funding acquisition: Rui Bao and Youfu Luo.

374

Investigation: Yang Yang,Yibo Zhu,Tao Yang,Tao Li, Yuan Ju, Yingjie Song, Jun He

375

and Huanxiang Liu.

376

Resources: Rui Bao and Youfu Luo.

377

Supervision: Tao Yang, Rui Bao and Youfu Luo.

378

Validation: Yang Yang, Yibo Zhu, Tao Yang, Rui Bao and Youfu Luo.

379

Visualization: Yang Yang, Yibo Zhu and Rui Bao.

380

Writing-original draft: Yang Yang, Yibo Zhu,Tao Yang, Rui Bao and Youfu Luo.

381

Writing-review & editing: Yang Yang, Rui Bao and Youfu Luo.

382

Competing interests

383

The authors declare no competing interests.

384

References

385
386
387
388
389
390
391
392
393
394
395
396
397
398

1.

Olivares AO, Baker TA, Sauer RT. Mechanistic insights into bacterial AAA+ proteases and
protein-remodelling machines. Nat Rev Microbiol. 2016;14(1):33-44. https://doi:10.1038/
nrmicro.2015.4 PMID:26639779.

2.

Bhandari V, Wong KS, Zhou JL, Mabanglo MF, Batey RA, Houry WA. The Role of ClpP
Protease in Bacterial Pathogenesis and Human Diseases. ACS Chem Biol. 2018;13(6):1413-25.
https://doi:10.1021/acschembio.8b00124 PMID:29775273.

3.

Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high
density mutagenesis. Mol Microbiol. 2003;48(1):77-84. https://doi:10.1046/j.13652958.2003.
03425.x PMID:12657046.

4.

Br√∂tz-Oesterhelt H, Beyer D, Kroll H-P, Endermann R, Ladel C, Schroeder W, et al.
Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat Med.
2005;11(10):1082-7. https://doi:10.1038/nm1306 PMID: 16200071

5.

Conlon BP, Nakayasu ES, Fleck LE, LaFleur MD, Isabella VM, Coleman K, et al. Activated
ClpP kills persisters and eradicates a chronic biofilm infection. Nature. 2013;503(7476):365-70.
18 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442

https://doi:10.1038/nature12790 PMID:24226776.
6.

Moreno-Cinos C, Sassetti E, Salado IG, Witt G, Benramdane S, Reinhardt L, et al. alpha-Amino
Diphenyl Phosphonates as Novel Inhibitors of Escherichia coli ClpP Protease. J Med Chem.
2019;62(2):774-97. https://doi:10.1021/acs.jmedchem.8b01466 PMID:30571121.

7.

Fraga H, Rodriguez B, Bardera A, Cid C, Akopian T, Kandror O, et al. Development of high
throughput screening methods for inhibitors of ClpC1P1P2 from Mycobacteria tuberculosis.
Anal Biochem. 2019;567:30-7. https://doi:10.1016/j.ab.2018.12.004.

8.

Markus Lakemeyer EB, Friederike M√∂ller, D√≥ra, Balogh RS, Hendrik Dietz, Stephan Axel,
Sieber. Tailored Peptide Phenyl Esters Block ClpXP Proteolysis by an Unusual Breakdown into
a Heptamer‚ÄìHexamer Assembly. Angew Chem Int Ed. 2019;58:1-7. https://doi:10.1002/anie.
201901056 PMID: 30829431

9.

Vahidi S, Ripstein ZA, Bonomi M, Yuwen T, Mabanglo MF, Juravsky JB, et al. Reversible
inhibition of the ClpP protease via an N-terminal conformational switch. Proc Natl Acad Sci U
S A. 2018;115(28):E6447-E56. https://doi:10.1073/pnas.1805125115 PMID: 29941580

10.

Ollinger J, O'Malley T, Kesicki EA, Odingo J, Parish T. Validation of the Essential ClpP
Protease in Mycobacterium tuberculosis as a Novel Drug Target. J Bacteriol. 2012;194(3):6638.

11.

Akopian T, Kandror O, Raju RM, Unnikrishnan M, Rubin EJ, Goldberg AL. The active ClpP
protease from M. tuberculosis is a complex composed of a heptameric ClpP1 and a ClpP2 ring.
EMBO J. 2012;31(6):1529-41. https://doi:10.1038/emboj.2012.5 PMID:22286948.

12.

Schmitz KR, Carney DW, Sello JK, Sauer RT. Crystal structure of Mycobacterium tuberculosis
ClpP1P2 suggests a model for peptidase activation by AAA+ partner binding and substrate
delivery. Proc Natl Acad Sci U S A. 2014;111(43):E4587-95. https://doi:10.1073/pnas.1417120111 PMID:25267638.

13.

Raju RM, Unnikrishnan M, Rubin DH, Krishnamoorthy V, Kandror O, Akopian TN, et al.
Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are
required for viability in vitro and during infection. PLoS Pathog. 2012;8(2):e1002511.
https://doi:10.1371/journal.ppat.1002511 PMID: 22359499

14.

Compton CL, Schmitz KR, Sauer RT, Sello JK. Antibacterial activity of and resistance to small
molecule inhibitors of the ClpP peptidase. ACS Chem Biol. 2013;8(12):2669-77.
https://doi:10.1021/cb400577b PMID:24047344.

15.

Akopian T, Kandror O, Tsu C, Lai JH, Wu W, Liu Y, et al. Cleavage Specificity of
Mycobacterium tuberculosis ClpP1P2 Protease and Identification of Novel Peptide Substrates
and Boronate Inhibitors with Anti-bacterial Activity. J Biol Chem. 2015;290(17):11008-20.
https://doi:10.1074/jbc.M114.625640 PMID:25759383.

16.

Moreira W, Ngan GJ, Low JL, Poulsen A, Chia BC, Ang MJ, et al. Target mechanism-based
whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in
mycobacteria. mBio. 2015;6(3):e00253-15. https://doi:10.1128/mBio.00253-15 PMID:25944857.

17.

Moreira W, Santhanakrishnan S, Ngan GJY, Low CB, Sangthongpitag K, Poulsen A, et al.
Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human
Proteasome. Antimicrob Agents Chemother. 2017;61(5). https://doi:10.1128/AAC.02307-16
PMID:28193668.

18.

Lee BG, Park EY, Lee KE, Jeon H, Sung KH, Paulsen H, et al. Structures of ClpP in complex
19 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486

with acyldepsipeptide antibiotics reveal its activation mechanism. Nat Struct Mol Biol.
2010;17(4):471-8. https://doi:10.1038/nsmb.1787 PMID:20305655.
19.

Li M, Kandror O, Akopian T, Dharkar P, Wlodawer A, Maurizi MR, et al. Structure and
Functional Properties of the Active Form of the Proteolytic Complex, ClpP1P2, from
Mycobacterium tuberculosis. J Biol Chem. 2016;291(14):7465-76. https://doi:10.1074/jbc.
M115.700344 PMID:26858247.

20.

Ingvarsson H, Mate MJ, Hogbom M, Portnoi D, Benaroudj N, Alzari PM, et al. Insights into the
inter-ring plasticity of caseinolytic proteases from the X-ray structure of Mycobacterium
tuberculosis ClpP1. Acta Crystallogr D Biol Crystallogr. 2007;63(Pt 2):249-59. https://doi:10.
1107/S0907444906050530 PMID:17242518.

21.

Sprangers R, Gribun A, Hwang PM, Houry WA, Kay LE. Quantitative NMR spectroscopy of
supramolecular complexes: dynamic side pores in ClpP are important for product release. Proc
Natl Acad Sci U S A. 2005;102(46):16678-83. https://doi:10.1073/pnas.0507370102 PMID:16263929.

22.

Gribun A, Kimber MS, Ching R, Sprangers R, Fiebig KM, Houry WA. The ClpP double ring
tetradecameric protease exhibits plastic ring-ring interactions, and the N termini of its subunits
form flexible loops that are essential for ClpXP and ClpAP complex formation. J Biol Chem.
2005;280(16):16185-96. https://doi:10.1074/jbc.M414124200 PMID:15701650.

23.

Zhang J, Ye F, Lan L, Jiang H, Luo C, Yang CG. Structural switching of Staphylococcus aureus
Clp protease: a key to understanding protease dynamics. J Biol Chem. 2011;286(43):37590-601.
https://doi:10.1074/jbc.M111.277848 PMID:21900233.

24.

Ye F, Zhang J, Liu H, Hilgenfeld R, Zhang R, Kong X, et al. Helix unfolding/refolding
characterizes the functional dynamics of Staphylococcus aureus Clp protease. J Biol Chem.
2013;288(24):17643-53. https://doi:10.1074/jbc.M113.452714 PMID:23625918.

25.

Gersch M, Kolb R, Alte F, Groll M, Sieber SA. Disruption of oligomerization and
dehydroalanine formation as mechanisms for ClpP protease inhibition. J Am Chem Soc.
2014;136(4):1360-6. https://doi:10.1021/ja4082793 PMID:24106749.

26.

Personne Y, Brown AC, Schuessler DL, Parish T. Mycobacterium tuberculosis ClpP Proteases
Are Co-transcribed but Exhibit Different Substrate Specificities. PLoS One. 2013;8(4):e60228.
https://doi:10.1371/journal.pone.0060228 PMID:23560081

27.

Szyk A, Maurizi MR. Crystal structure at 1.9A of E. coli ClpP with a peptide covalently bound
at the active site. J Struct Biol. 2006;156(1):165-74. https://doi:10.1016/j.jsb.2006.03.013
PMID:16682229.

28.

Mundra S, Thakur V, Bello AM, Rathore S, Asad M, Wei L, et al. A novel class of Plasmodial
ClpP protease inhibitors as potential antimalarial agents. Bioorg Med Chem. 2017;25(20):566277. https://doi:10.1016/j.bmc.2017.08.049 PMID:28917450.

29.

Liu K, Ologbenla A, Houry WA. Dynamics of the ClpP serine protease: a model for selfcompartmentalized

proteases.

Crit

Rev

Biochem

Mol

Biol.

2014;49(5):400-12.

https://doi:10.3109/10409238.2014.925421 PMID:24915503.
30.

Lee BG, Kim MK, Song HK. Structural insights into the conformational diversity of ClpP from
Bacillus subtilis. Molecules and cells. 2011;32(6):589-95. https://doi:10.1007/s10059-0110197-1 PMID:22080375.

31.

Geiger SR, Bottcher T, Sieber SA, Cramer P. A conformational switch underlies ClpP protease
function. Angew Chem Int Ed. 2011;50(25):5749-52. https://doi:10.1002/anie.201100666
20 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530

PMID:21544912.
32.

Dougan DA, Hantke I, Turgay K. Dysregulating ClpP: From Antibiotics to Anticancer? Cell
Chem Biol. 2018;25(8):929-30. https://doi:10.1016/j.chembiol.2018.08.002 PMID:30118671.

33.

Hackl MW, Lakemeyer M, Dahmen M, Glaser M, Pahl A, Lorenz-Baath K, et al. Phenyl Esters
Are Potent Inhibitors of Caseinolytic Protease P and Reveal a Stereogenic Switch for
Deoligomerization. J Am Chem Soc. 2015;137(26):8475-83. https://doi:10.1021/jacs.5b03084
PMID:26083639.

34.

Hall BM, Breidenstein EBM, de la Fuente-Nunez C, Reffuveille F, Mawla GD, Hancock REW,
et al. Two Isoforms of Clp Peptidase in Pseudomonas aeruginosa Control Distinct Aspects of
Cellular Physiology. J Bacteriol. 2017;199(3). https://doi:10.1128/JB.00568-16 PMID:27849175.

35.

Gronauer TF, Mandl MM, Lakemeyer M, Hackl MW, Messner M, Korotkov VS, et al. Design
and synthesis of tailored human caseinolytic protease P inhibitors. Chem Commun (Camb).
2018;54(70):9833-6. https://doi:10.1039/c8cc05265d PMID:30109319.

36.

Zhang Z-M, Ma K-W, Yuan S, Luo Y, Jiang S, Hawara E, et al. Structure of a pathogen effector
reveals the enzymatic mechanism of a novel acetyltransferase family. Nat Struct Mol Biol.
2016;23(9):847-52. https://doi:10.1038/nsmb.3279 PMID:27525589.

37.

Z O, W M. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol.
1997;276(97):307-26 PMID:27754618.

38.

Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a
comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D
Biol Crystallogr. 2010;66(Pt 2):213-21. https://doi:10.1107/S0907444909052925 PMID:20124702.

39.

Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta
Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486-501.

https://doi:10.1107/S09074449100-

07493 PMID:20383002.
40.

Holdgate GA, Ward WHJ. Measurements of binding thermodynamics in drug discovery. Drug
Discov Today. 2005;10(22):1543-50. https://doi:10.1016/s1359-6446(05)03610-x PMID:
16257377

41.

D. A. Case TAD, T. E. Cheatham III, C. L.Simmerling, J. Wang, R. L. R. E. Duke, W. Z. R. C.
Walker, K. M. Merz, B. Roberts, S. Hayik, A. Roitberg, J. S. G. Seabra, I. K. A. W. Goetz, F. P.
K. F. Wong, J. Vanicek, R. M. Wolf, J. Liu, S. R. B. X. Wu, T. Steinbrecher, H. Gohlke, Q. Cai,
X. Ye, J. Wang, M.-J. Hsieh, G. Cui, D. R. Roe, D. H. Mathews, M. G. Seetin, R. SalomonFerrer, C. Sagui, V. Babin, T. Luchko, S. Gusarov, A. Kovalenko and P. A. Kollman. Amber 14.
San Francisco: University of California; 2014.

42.

Schr√∂dinger L. The PyMOL molecular graphics system, version 1.8. New York: ; 2015.

43.

Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple
Amber force fields and development of improved protein backbone parameters. Proteins.
2006;65(3):712-25. https://doi:10.1002/prot.21123 PMID:16981200.

44.

Roe DR, Cheatham TE, 3rd. PTRAJ and CPPTRAJ: Software for Processing and Analysis of
Molecular Dynamics Trajectory Data. Journal of chemical theory and computation.
2013;9(7):3084-95. https://doi:10.1021/ct400341p PMID:26583988.

45.

Junmei Wang, Main M. Wolf, James W, Caldwell, Peter A. Kollman, Case. DA. Development
and Testing of a General Amber Force Field. J Comput Chem. 2004;25(9):1157-74.
21 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

531
532
533
534
535
536
537

https://doi:10.1002/jcc.20035 PMID:15116359.
46.

Glykos NM. Software news and updates. Carma: a molecular dynamics analysis program. J
Comput Chem. 2006;27(14):1765-8. https://doi:10.1002/jcc.20482 PMID:16917862.

47.

Papaleo E, Mereghetti P, Fantucci P, Grandori R, De Gioia L. Free-energy landscape, principal
component analysis, and structural clustering to identify representative conformations from
molecular dynamics simulations: the myoglobin case. J Mol Graph Model. 2009;27(8):889-99.
https://doi:10.1016/j.jmgm.2009.01.006 PMID:19264523.

538
539

22 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

540

Figures legends

541

Fig 1. Cediranib inhibits Mycobacterium tuberculosis (Mtb) caseinolytic protease

542

P1P2 (MtbClpP1P2) activity. (A) Chemical structure of compounds for secondary

543

screening. (B) Cediranib inhibits MtbClpP1P2 cleavage of substrate Z-Gly-Gly-Leu-

544

AMC in a peptidase assay. Concentrations of MtbClpP1P2 and Z-Gly-Gly-Leu-AMC

545

were 0.5 ŒºM and 100 ŒºM, respectively. (C) Noncompetitive inhibition of MtbClpP1P2

546

cleavage of Z-Gly-Gly-Leu-AMC by cediranib. Cediranib increased the maximum

547

reaction velocity (Vmax), but did not affect the Michaelis constant (Km) of the

548

MtbClpP1P2 reaction.

549

Fig 2. Cediranib-bound ClpP1P2 structures. (A) Side view of the MtbClpP1P2

550

tetradecamer. The MtbClpP1 heptamer (cyan subunits) and MtbClpP2 heptamer

551

(orange subunits) are shown in cartoon representation. Spheres represent cediranib

552

molecules (green) bound to the MtbClpP1 ring and Bz-Leu-Leu (Bz-LL) peptide

553

(yellow) bound to the active sites of both rings. (B) Top panel, axial view of the

554

MtbClpP1P2 tetradecamer from the MtbClpP1 side; bottom panel, axial view of the

555

MtbClpP1P2 tetradecamer from the MtbClpP2 side. (C) MtbClpP1P2 monomer

556

magnified from cediranib-bound MtbClpP1P2 structure. Secondary structure elements

557

are labeled. The MtbClpP1P2 handle region and the catalytic triad residues are labeled.

558

Cediranib and Bz-LL are colored green and yellow, respectively.

559

Fig 3. Structural details of cediranib binding pocket in MtbClpP1. (A) The activator

560

is bound in opposite orientations in MtbClpP1 and MtbClpP2. Bz-LL in MtbClpP1 is

561

colored yellow and Bz-LL in MtbClpP2 is colored gray. (B) 2Fo‚àíFc electron-density

562

map of cediranib in MtbClpP1. (C) Surface representation of the MtbClpP1P2

563

tetradecamer with bound cediranib reveals that cediranib binds in a novel site. (D) A

564

cartoon representation of the cediranib interactions with MtbClpP1. (E) Molecular

565

interactions between cediranib and residues in the binding pocket. Cediranib does not

566

interact directly with the active site, but interferes with the presumably defined

567

equatorial pores and dynamic handle regions. (F) Detailed view of the cediranib-bound
23 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

568

pocket formed by residues Gln142‚ÄìGlu149 in Œ±5, Ile71‚ÄìAla76 in Œ±3, and three short Œ≤-

569

sheets (Œ≤D, Œ≤F, Œ≤H) from the neighboring MtbClpP1 subunit.

570

Fig 4. Importance of the handle domain and analysis of distinct ClpP sequences.

571

Importance of the handle domain and analysis of distinct ClpP sequences. (A)

572

Superposition and ribbon representation of the monomeric structures of MtbClpP1

573

(cyan), MtbClpP2 (orange), Staphylococcus aureus (Sa)ClpP (green), Escherichia coli

574

(Ec)ClpP (light blue), Listeria monocytogenes (Lm)ClpP1 (pink), LmClpP2 (magenta),

575

and human (h)ClpP (gray). (B) MtbClpP1P2 side views. Mutant residue sites are labeled.

576

Spheres represent cediranib molecules (green) bound to the MtbClpP1 ring and Bz-Leu-

577

Leu (Bz-LL) peptide (yellow) bound to the active sites of both rings. (C) Sequence

578

alignment and secondary structure assignment of ClpPs. Sequence alignment was

579

performed in BioEdit. Identical residues are highlighted in blue. Secondary structure

580

elements present in the MtbClpP1P2 structure (PDB code 6IW7) are shown on the top

581

of the sequence alignment.

24 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

582

Supporting Information

583

S1 Table. Plasmids used in this study.

584

(DOCX)

585

S2 Table. Primers used in this study.

586

(DOCX)

587

S3 Table. Strains used in this study.

588

(DOCX)

589

S1 Fig. Differential scanning calorimetry analysis of the binding between

590

cediranib and MtbClpP1P2. The concentrations of bortezomib and cediranib were 100

591

ŒºM.

592

(TIF)

593

S2 Fig. Inhibition of cediranib aganist EcClpP, SaClpP, PaClpP and hClpP.

594

(A) Inhibition of cediranib on EcClpP. Concentration of EcClpP was 0.5ŒºM. (B)

595

Inhibition of cediranib on SaClpP. Concentration of SaClpP was 2.5 ŒºM. (C) Inhibition

596

of cediranib on PaClpP. Concentration of PaClpP was 0.5 ŒºM. (D) IC50 value of

597

cediranib aganist hClpP. Concentration of hClpP was 2.5ŒºM.

598

(TIF)

599

S3 Fig. Conformational changes of MtbClpP1 dimer.

600

(A,C). CŒ± RMSD values of the head domain and handle domain in MtbClpP1 dimer

601

versus simulation time without (A)or with cediranib(C). The RMSD values of the head

602

domain and handle domain are shown in green and red, respectively. (B,D). Secondary

603

structures as a function of time for MtbClpP1 dimer without (B)or with cediranib(D) in
25 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

604

trajectory as calculated using DSSP. The structures were analyzed every 100 ps. (E,F).

605

Left, energy landscape for the conformational transition of MtbClpP1 dimer without

606

(E)or with cediranib(F). Reaction coordinates were defined according to PC1 and PC2

607

obtained from PCA. Right,snapshot structures of Œ±5 from MtbClpP1 dimer without

608

(E)or with cediranib(F) extracted from the trajectory.

609

(TIF)

610

26 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

611

Table 1. Minimum inhibitory concentrations (MIC) against different bacterial

612

strains and the inhibition of ClpP peptidase activity by cediranib.
Organism

MIC ÔºàŒºg/mLÔºâ

IC50ÔºàŒºMÔºâ

Selectivity Indexb

M. tuberculosis H37Rv
M. smegmatis MC2155
E. coli
S. aureus
P. aeruginosa
Homo sapiens

16
64
>128
>128
>128
/

3.4¬±0.7
NTa
>100
>100
>100
36.6¬±0.5

/
NT
>30
>30
>30
10.8

613

a

NT, not tested. b Selectivity Index calculated as Cediranib IC50 of ClpPs / cediranib

614

IC50 of MtbClpP1P2.

615

27 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

616

Table 2. Minimum inhibitory concentration of cediranib against different strains.

ATCC25922
ATCC35218
ATCC33591
ATCC25923
B27
ATCC12228

Cediranib
(Œºg/mL)
>128
>128
>128
>128
64
64

Linezolid
(Œºg/mL)
>128
>128
2
2
1
1

Rifampin
(Œºg/mL)
4
4
0.06
0.06
0.06
0.06

Bortezomib
(Œºg/mL)
>128
>128
>128
>128
>128
>128

ATCC33186

>128

2

4

>128

ATCC35667

128

2

16

>128

ATCC27853
C58
ATCC4352
ATCC700603

>128
>128
64
>128

>128
>128
32
>128

32
32
8
32

>128
>128
>128
>128

Strains
Escherichia coli
Staphylococcus
aureus
Staphylococcus
epidermidis
Enterococcus
faecalis
Enterococcus
faecium
Pseudomonas
aeruginosa
Klebsiella
pneumoniae
617

Overall structure of cediranib-bound MtbClpP1P2

618

28 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

619

620
621
622
623
624
625

Table 3. Data collection and refinement statistics.
Parameters

MtbClpP1P2¬∑Cediranib¬∑Bz-LL

Data collection
Space group
a, b, c(√Ö)
Œ±, Œ≤, Œ≥(¬∞)
Wavelength(√Ö)
Resolution(√Ö)
CC1/2
Unique reflections
Rmeas(%)a

C121
210.63 180.78 95.93
90.00 95.72 90.00
0.97915
40.00 - 2.69(2.69 - 2.60)
0.986(0.376)
96900(9595)
20.8(134)

Mean I/œÉ(I)a

8.04(1.04)

Completeness(%)a

98.6(98.2)

Redundancy
Refinement
Resolution(√Ö)
Rwork/Rfreeb
No.atoms
Protein
Cediranib
Z-LL
Water
Œ≤-factors
Protein
Cediranib
Z-LL
Water
R.m.s. deviations
Bond lengths(√Ö)
Bond angles(¬∞)
Ramachandran plot
Favored (%)
Allowed (%)
Outliers (%)

4.9(4.1)
39.84 ‚Äì 2.69
0.2002/0.2433
19747
413
350
187
49.86
68.36
55.26
48.67
0.009
1.097
97.08
2.73
0.19

a

The values in parentheses are for the outermost shell.
is the Rwork based on 5% of the data excluded from the refinement.
ùëÖmeas = ‚àë‚Ñéùëòùëô ‚àöùëõ/(ùëõ ‚àí 1) ‚àëùëõùëñ=1|Ii (‚Ñéùëòùëô) ‚àí ‚å©I(‚Ñéùëòùëô)‚å™| / ‚àë‚Ñéùëòùëô ‚àëùëñ Ii (‚Ñéùëòùëô) , where ‚å©I(‚Ñéùëòùëô)‚å™
is the mean intensity of a set of equivalent reflections.
bR
free

ùëÖwork = ‚àë‚Ñéùëòùëô‚ÄñFobs | ‚àí ÔΩúFcalc ‚Äñ / ‚àë‚Ñéùëòùëô ÔΩúFobs ÔΩú, where Fobs and Fcalc are observed and
calculated structure factors, respectively.
29 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

626

Table 4. Mutagenesis analysis of MtbClpP1.
Mutant

Activity

IC50ÔºàŒºMÔºâ

Cediranib inhibition

3.4¬±0.7

Cc
Rd

a

/

+++++

I71F
I71V

‚àíb
+/‚àí

>54.5

S72T

+

NTe

M75A
M75F

‚àí
‚àí

M75L

+

NT
f

M75D

N/A

M95A

‚àí

M95Q

++++++++

23.7¬±0.7

R

M95L

++++

7.5¬±0.9

C

M95W

>50

R

R119E

‚àí
+/‚àí
‚àí

R119Q

+

42.2¬±0.7

R

R119S

++

14.4¬±0.7

C

Q142H

+++

9.5¬±0.7

C

Q142R
I146M

‚àí
‚àí

I146V

+

5.1¬±0.7

C

I146T

+

9.7¬±1.3

C

I146L

‚àí

E149L

++++

41.8¬±0.9

R

E149R

+

>100

R

E149K

+

6.3¬±0.7

C

E149Q

++++++

7.6¬±0.9

C

E149 T

+++

12.8¬±0.8

C

W174I

‚àí
+/‚àí
‚àí

20.2¬±0.7

R

M95S

W174F
W174A
a

628

enzyme activity; c C, similar to wild-type MtbClpP1 (the control); d R, more resistant

629

than wild-type MtbClpP1 (R is defined as IC50 value of mutant protein/IC50 value of

630

wild-type protein >5); e NT, not tested; f N/A, protein unstable.

+, Having enzyme activity (the more plus signs, the higher the activity);

30 / 42

b

‚àí, No

627

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

631
632

Figure 1

633

31 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

634

635
636

Figure 2

637

32 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

638

639
640

Figure 3

641

33 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

642
643

Figure 4

644
645

34 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

646

S1 Table. Plasmids used in this study.
Plasmid

Feature

Reference

pRSF-duet-1-MtbClpP1

For expressing MtbClpP1 protein

This study

pRSF-duet-1-MtbClpP2

For expressing MtbClpP2 protein

This study

pRSF-duet-1-EcClpP

For expressing EcClpP protein

This study

pRSF-duet-1-PaClpP1

For expressing PaClpP1 protein

This study

pRSF-duet-1-SaClpP

For expressing SaClpP protein

This study

pRSF-duet-1- hClpP

For expressing hClpP(ÔÅÑC) protein

This study

647
648

35 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

649

S2 Table. Primers used in this study.
Gene

Primers
CAGATTGGTGGATCCATGCGTTCGAACTCGC

MtbClpP1-Forword
AG
TTTACCAGACTCGAGTCACTGTGCTTCTCCA
MtbClpP1-Reverse
TTGAC
CAGATTGGTGGATCCCGCTACATCCTGCCGT
MtbClpP2-Forword
CGTTC
TTTACCAGACTCGAGTCAGGCGGTTTGCGCG
MtbClpP2-Reverse
GAGAG
RSF-duet-1-Forword

CTCGAGTCTGGTAAAGAAACCG

RSF-duet-1- Reverse

GGATCCACCAATCTGTTCTCTG
GAGAACAGATTGGTGGATCCCCGCTCATTCC

hClpP- Forword
CATCGTG
GTTTCTTTACCAGACTCGAGGGTGCTAGCTG
hClpP- Reverse
GGACAGGTTC
GAGAACAGATTGGTGGATCCATGTCATACA
EcClpP- Forword
GCGGCGAAC
GTTTCTTTACCAGACTCGAGTCAATTACGAT
EcClpP- Reverse
GGGTCAGAATC
GAGAACAGATTGGTGGATCCATGTCTCGCA
PaClpP1- Forword
ACTCTTTTAT TC
GTTTCTTTACCAGACTCGAGTTAGACGGCCA
PaClpP1- Reverse
G GTCGCGCTG
I71V- Forword

GTC AGCGCCGGCATGGCGATC

I71V- Reverse

CGATCCACCCGGCGAATTGAT

M75L- Forword

CTT GCGATCTACGACACCATG

M75L- Reverse

GCCGGCGCTGATCGATCCAC
36 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

M75D- Forword

GAC GCGATCTACGACACCATG

M75D- Reverse

GCCGGCGCTGATCGATCCAC

M95L- Forword

C TT GCCGC CTCGATGGGC GAG

M95L/W/S- Reverse

GCCCATCGCG TAGGTGGC

M95W- Forword

T GG GCCGC CTCGATGGGC GAG

M95S- Forword

TCG GCCGC CTCGATGGGC GAG

R119E- Forword-1

GAAATCCTGATGCACCAGCCG

R119E/Q/S-Reverse-1

AGCATGCGGCAGCGCGTAG

R119Q-Forword-1

CAG ATCCTGATGCACCAGCCG

R119S- Forword-1

TCG ATCCTGATGCACCAGCCG
GCTACGCGCTGCCGCATGCTGAAATCCTGAT

R119E-Forword-2
GCACC AGCCGTTG
GCTACGCGCTGCCGCATGCTCAGATCCTGAT
R119Q-Forword-1
GCACCAGCCGTTG
GCTACGCGCTGCCGCATGCTTCGATCCTGAT
R119S- Forword-1
GCACC AGCCGTTG
R119E/Q/S-Reverse-2

AGCATGCGGCAGCGCGTAG

E142H- Forword

CACTTCGCCGTGATCAAGAAAG

E142H- Reverse

CTCGGCCTGGATGGCGATATC

E142R- Forword

CGC TTCGCCGTGATCAAGAAAG

E142R- Reverse

CTCGGCCTGGATGGCGATATC

I146V- Forword

GTCAAGAAAGAAATGTTCCGGC

I146V/L/T- Reverse

CACGGCGAACTGCTCGGC

I146L- Forword

C TT AAGAAAGAAATGTTCCGGC

I146T- Forword

ACT AAGAAAGAAATGTTCCGGC

E149L- Forword

CTTATGTTCCGGCTCAACGCCG

E149L/R/K/Q/T- Reverse TTTCTTGATCACGGCGAACTG
E149R- Forword

CGC ATGTTCCGGCTCAACGCCG

E149K- Forword

AA G ATGTTCCGGCTCAACGCCG
37 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

E149Q- Forword

CAG ATGTTCCGGCTCAACGCCG

E149 T- Forword

ACT ATGTTCCGGCTCAACGCCG

650

38 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

651

S3 Table. Strains used in this study.
Strains

Feature

Source

E. coli strains DH5Œ±

For amplification of plasmid

TransGen Biotech

E. coli strains BL21(DE3)

For expressing protein

TransGen Biotech

Staphylococcus aureus

MIC

ATCC33591
ATCC25923
B27
Staphylococcus epidermidis

MIC
ATCC12228

Enterococcus faecalis

MIC

ATCC33186

Enterococcus faecium

MIC

ATCC35667

Pseudomonas aeruginosa

MIC

ATCC27853
C58
ATCC4352
Klebsiella pneumoniae

MIC
ATCC700603
ATCC25922

Escherichia coli

MIC
ATCC35218

Mycobacterium smegmatis
MC2155

MIC

ATCC 700084

MIC

ATCC 27294

Mycobacterium tuberculosis
H37Rv
652
653

39 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

654
655

S1 Fig

656

40 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

657
658

S2 Fig

659

41 / 42

bioRxiv preprint doi: https://doi.org/10.1101/713214; this version posted July 24, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1

660
661

S3 Fig
42 / 42

